Integrated Nanotherapeutics Inc. is a biopharmaceutical company dedicated to the development of novel drugs in the areas of cancer and autoimmunity, including diabetes, where there is significant unmet medical need for therapeutic agents with improved activity. Our proprietary technologies allow the incorporation of any compound in lipid nanoparticle delivery systems and thus extend the benefits of delivery systems to virtually any therapeutic and diagnostic agent. We envision that many existing drugs or agents can be made much safer and more effective using our technologies.
View Top Employees from Integrated Nanotherapeutics Inc.Website | https://www.integratedntx.com |
Revenue | $6 million |
Employees | 13 (9 on RocketReach) |
Address | 4475 Wayburne Drive, Suite 205, Burnaby, British Columbia V5G 4X4, CA |
Phone | (778) 819-1622 |
Technologies |
JavaScript,
HTML,
Twitter
+5 more
(view full list)
|
Industry | Biotechnology, Manufacturing General, Manufacturing |
Competitors | Medesis Pharma, Monogenic Pharmaceuticals, Naegis Pharmaceuticals Inc, Wyvern Pharmaceuticals Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular Integrated Nanotherapeutics Inc. employee's phone or email?
The Integrated Nanotherapeutics Inc. annual revenue was $6 million in 2024.
Azadeh Goudarzi is the Director of Business Development and Innovation of Integrated Nanotherapeutics Inc..
9 people are employed at Integrated Nanotherapeutics Inc..
Integrated Nanotherapeutics Inc. is based in Burnaby, British Columbia.
The NAICS codes for Integrated Nanotherapeutics Inc. are [3254, 325, 32541, 32].
The SIC codes for Integrated Nanotherapeutics Inc. are [28, 283].